ADVANCING MANUFACTURE OF CELL AND GENE THERAPIES VII

An ECI Conference Series

Feb 6-10, 2022
Loews Coronado Bay Hotel
Coronado, CA

Request for Next Mailing

About This Conference

The ECI Advancing Manufacture of Cell and Gene Therapies conference is a biennial meeting that brings together leading figures from academia and industry to showcase and debate the latest breakthroughs in advancing engineering and manufacturing of next generation therapies. 

This 2021 event will provide interactive opportunities for a diverse set of attendees, ranging from trainees to experienced practitioners, to examine the latest advances in product manufacture, analytics, non-viral gene delivery, cell engineering and the future of product release (detailed information on each session provided below).

Conference Chairs

Sean Palecek, University of Wisconsin, USA
Damian Marshall, Achilles Therapeutics, UK
Fernanda Masri, Cell & Gene Therapy Catapult, UK

Steering Committee 

Dolores Baksh (Akron Bio, USA)
Mike Betenbaugh (Johns Hopkins University, USA)
Tom Brieva (Tmunity Therapeutics, USA)
Barry Buckland, Chair (BiologicB,LLC, USA)
Manuel Carrondo (IBET – Instituto de Biologia Experimental e Tecnológica, Portugal)
Peter Gray (AIBN – University of Queensland, Australia)
Chris Mason (Avro Bio, United Kingdom)
Bill Miller (Northwestern University, USA)
Lars Nielsen (The University of Queensland, Australia)
Rod Rietze (iVexSol, Inc., USA)
Greg Russotti (Century Therapeutics, USA)
Ivan Wall (Aston University, United Kingdom)
Peter Zandstra (University of British Columbia, Canada)

Organizing Committee

Paula Alves, IBET & ITQB, Portugal
Sven Ansorge, ExCellThera, Canada
Stefano Baila, Anemocyte, Italy
Ricardo Baptista, Procella Therapeutics, Sweden
Nina Bauer, MilliporeSigma, USA
Lorraine Borland, Sartorius, UK
Amit Chandra, YPOSKESI, France
Elizabeth Cheeseman, Independent Consultant, UK
Tania Pereira Chilima, Univercells Technologies, Belgium
Gisele Deblandre, Cellbox Solutions GmbH, Germany
Jo Mountford, SNBTS Advanced Therapeutics, Scotland
Clive Glover, Pall, UK
Azadeh Golipour, AVROBIO, USA
Mike Kallos, University of Calgary, Canada
Masahiro Kino-oka, Osaka University, Japan
Todd McDevitt, Gladstone Institutes, USA
Chris Moore, Exact Sciences, USA
Nicholas Ostrout, Lonza, US
Qasim Rafiq, University College London, UK
David Schaffer, University of California-Berkeley, USA

Conference Program

Conference Opening Ceremony Fireside Chat: Where is the cell and gene therapy field heading and how can we increase patient access

Moderator:
Sean Palecek, University of Wisconsin, USA

Panelists:

  • Boro Dropulic – Caring Cross, USA
  • Krishnendu Roy – Georgia Tech, USA
  • Gregory Russotti – Century Therapeutics, USA
  • Phil Vanek – Gamma Biosciences, USA

Conference Sessions

Gene editing and emerging technologies

Session Chairs: 

Ricardo Baptista, Procella Therapeutics, Sweden
Krishanu Saha, University of Wisconsin, USA

Session Scope:

This session focuses on state-of-the-art technologies, technical advancements, and challenges to implementing gene delivery and editing methods that support the manufacture of gene-edited products, including gene therapies and cell-based products for autologous and allogeneic therapies. 

Confirmed Speakers:

Keynote – Michele Sadelain, Memorial Sloan Kettering – USA
Samir El Andaloussi, Karolinska Institute – Sweden
Tom Brieva – Tmunity Therapeutics – USA

Invited Speakers:

Boon Hwa Neo, Lonza – USA
Alois Jungbauer, University of Vienna – Austria
Lili Belcastro, Bristol Myers Squibb – USA
Lauren Sarko, University of Wisconsin-Madison – USA

Advances in viral vector manufacturing

Session Chairs: 

Sven Ansorge, ExCellThera, Canada
Paula Alves, IBET, Portugal

Session Scope:

Viral vector manufacturing presents a significant bottleneck to further advance cell and gene therapies. This session will provide an overview of current state-of-the art industrial viral vector manufacturing while also highlighting strategies that are currently explored in R&D settings to reduce viral vector capacity constraints currently faced by the field. 

Confirmed Speakers:

Keynote: David Schaffer, University of California – Berkeley, USA
Ying Jing, 2Seventy Bio, USA
Manny Otero, Turnstone Biologics, USA
Konstantin Konstantinov, Codiak Bioscience – USA

Invited Speakers:

Gwendal Gränicher, Max Planck Institute – Germany
Annabel Lyle, University College London – UK
Kory Blocker, University of Pennsylvania – USA
Nripen Singh, Passage Bioscience – USA
Carme Ripoll Fiol, University College London – UK
Tania Pereira Chilima, Univercells Technologies– Belgium

Advances in cell therapy manufacturing

Session Chairs: 

Jo Mountford, SNBTS, Scotland
Masahiro Kino-oka, Osaka University, Japan

Session Scope:

Many of the emerging technologies in cell production have led to more stable manufacturing processes; however, these have tended to be cell type, or product, specific. It is essential to capture and apply common lessons from these developments to a wider range of products, in particular those that require multi-phase processing with widely differing requirements (e.g. iPSC-derived cell products).  Further, increasingly complex products (combining genetic modification, cell differentiation, etc.) necessitate the development of new manufacturing, monitoring, and analytics technologies that improve process stability, efficiency, and robustness. 

Confirmed Speakers:

Keynote: Jen Moody, Pall Corporation – Canada 
Allan Dietz, Mayo Clinic – USA
Rupa Pike, Thermo Fisher Scientific – USA
Ricardo Baptista, Procella Therapeutics – Sweden

Invited Speakers:

Rui Li, University of Minnesota – USA
Jeff Zurawski, DiscGenics – USA
Ioannnis Papantoniou, Katholieke Universiteit Leuven – Belgium
Sho Sato, Fujifilm Cellular Dynamics – USA
Lavanya Peddada, Century Therapeutics – USA
Bryan Wang, Georgia Tech – USA

Analytics and big data

Session Chairs: 

Behnam Ahmadian Baghbaderani, Lonza, USA 
Boyan Yordanov, Scientific Technologies, UK

Session Scope:

As the cell and gene therapy fields continue to advance, we are using larger and more complex data sets to generate a deeper understanding of product quality and to derive control strategies to improve product manufacture.  However, deriving process understanding from big data remains difficult.  

Confirmed Speakers:

Keynote – Dayue Chen, Genentech – USA
Nicholas Clarkson, Oxford Biomedica – UK
Susanne Rafelski, Allen Institute for Cell Science – USA
Marc-Olivier Baradez, Cell and Gene Therapy Catapult – UK

Invited Speakers:

James Colter, University of Calgary – Canada
Shreyas Rangan, University of British Columbia – Canada
Roland Ashton, Bristol Myers Squibb – USA

Session 5: The future of product release

Session Chairs: 

Lorraine Borland, Sartorius Stedim Biotech, UK 
Azadeh Golipour, AVROBIO, USA

Session Scope:

Whilst bioproduction methods and in-process analytics become ever more complex for cell and gene therapy products, regulatory lot release remains highly dependent on traditional testing approaches. In order to meet our industry needs for the rapid release of these products whilst meeting regulatory standards we must look to new quality control strategies and innovative methodologies. In this session we will explore the regulatory challenges, our current limitations and technology gaps and how we can address these points. 

Confirmed Speakers:

Keynote – Yan Zhang, Mission Bio– USA
Luca Biasco, AvroBio – USA
Stuart Wright, Sartorius Stedim Biotech, UK 
Amy Glekas, MilliporeSigma – USA

Invited Speakers:

Ian Anderson, Pharmaron – UK
Lily Li, Cell and Gene Therapy Cataput – UK
Purna Venkataraman, Bluebird Bio – USA

Pre-Conference Workshop

Workshop chairs:

Thomas Heathman, Ori Biotech North America, USA

Nina Bauer, MilliporeSigma, USA

Carolyn Yeago, Georgia Tech, USA

Workshop Contact Email:  cgt2022preconfws@engconfintl.org

ECI Pre-Conference Workshop

How Can Analytics Enable Manufacturing Automation, Process Robustness, and Deliver Patient Access to Life-Saving Cell-Based Therapies?

Background

Cell-based therapy manufacturing is a complex, often manual, time- and labor-intensive process. As a consequence, price tags remain high, and treatments are only available to a select few. While the focus is typically on manual labor and lack of automation, product understanding is another component that contributes to the complexity. For true process automation to enable scalability in the cell-based therapy industry, analytical methods must be developed and implemented that have a path to becoming fully integrated into cell-based therapy manufacturing processes. 

Overview

In this workshop, you will learn from and work with preeminent industry and academic experts to assess the role testing and analytics will play in enabling next-generation cell-based therapymanufacturing.

This will be approached in four consecutive sessions:

1. Lessons from Past Experience: Learning from the previous biopharmaceutical industries (e.g. monoclonal antibody industry) to identify core gaps in establishing efficient testing and characterization paradigms for cell-based therapy products.

2. Solutions and Technologies: Identifying existing and emerging technologies to address these gaps in the mid-term and explore application to product characterization and drug discovery.

3. Impact Assessment: Assessing the integration of routine testing and manufacturing automation and discussing next steps in process and analytical optimization and standardization.

4. Building a Roadmap: Defining a development plan and identifying appropriate industry and academic sectors for enablement of the generated solutions. 

Audience and Outcomes

The workshop is aimed at members of the cell-based therapy industry at all levels of technical expertise that want to understand and discuss the role of analytical methods in enabling manufacturing automation. Bringing together a broad range of backgrounds and experiences will help the attendees to develop a deeper understanding of cell-based therapy product testing. Through case study-led workshops, the participants will assess the current state of the cell-based therapy industry and work jointly on a roadmap for implementing analytical methods that will enable manufacturing automation based on profound product understanding.

Confirmed Speakers

  • Damian Marshall, Achilles Therapeutics, UK
  • Taby Ahsan, MD Anderson Cancer Center, USA
  • Scott Jackson, NIST, USA
  • Joseph Valdez, Berkeley Lights, Inc., USA
  • John Churchwell, Cell & Gene Therapy Catapult, UK

Best Poster Presentation Award

Aaron Simmons

University of Wisconsin – Madison
“Systems-level discovery of quality attributes and candidate pathways for optimized production of human pluripotent stem cell-derived cardiomyocytes”

Runner-Up: Tiffany Hood

University College London, UK
“Process development for improved Car-t production
utilizing an automated perfusion stirred-tank bioreactor”

Runner-Up: Joana I. Almeida

IBET, ITQB, Portugal
“A nature-inspired protocol to generate mature hiPSC-derived
hepatocytes: Unveiling the role of human intestinal microbiome”

Christopher Hewitt Outstanding Young Investigator Award

ECI is pleased to announce that Andy Tay Kah Ping (Imperial College London/National University of Singapore) is the winner of the first Christopher Hewitt Outstanding Young Investigator Award.

Venue Information

The conference will take place at Loews Coronado Bay Hotel (4000 Coronado Bay Road, Coronado, California).  Set on Coronado Bay directly across the street from Silver Strand State Beach, the hotel is just over two miles to San Diego National Wildlife Refuge Complex. The hotel is set on a 15-acre peninsula with beach access via a pedestrian underpass.  The multi-building, three-floor resort offers 439 rooms and suite that are light and airy. Room views include bay, marina, pool or gardens. There is free Wi-Fi and the rooms have Keurig coffeemakers and ample outlets. The hotel has tennis courts, bicycle rentals, a fitness center, spa and three swimming pools.  Both self and valet parking are available for an additional fee.

San Diego attractions such as the San Diego Zoo, Balboa Park and the Gaslamp Quarter are each approximately a 25 minute trip from the hotel.

Sponsor Logos

Gates Foundation

Sponsor Packages

Package A – Basic sponsorship: $3,000 

• Name of Company on Sponsor List in program 

Package A+ – Basic social event sponsorship (limit 3 – first come first served): $4,500 • Name of Company on Sponsor List in program 

• Branding (banner) at evening social event 

Package B – Sponsor a break: $6,000  

• Name of Company on Sponsor List in program 
• Named sponsor at an event (e.g., coffee break, poster session) 
• Full page advertisement in program 
• Company logo and link on conference website 
• Company logo displayed on screen between sessions 

Package B+ – Advanced social event sponsorship (limit 1 – first come first served): $7,500

• Name of Company on Sponsor List in program 
• Branding (banner) at evening social event (banner to be provided by sponsoring company) • Brief (< 3 min) welcome address at social event 
• Name of Company on Sponsor List in program 
• Named sponsor at an event (e.g., coffee break, poster session) 
• Full page advertisement in program 
• Company logo and link on conference website 
• Company logo displayed on screen between sessions 

Package C – Exhibit and attend: $12,500 

• Name of Company on Sponsor List in program 
• Full page advertisement in program 
• Company logo and link on conference website 
• Company logo displayed on screen between sessions 
• Table display 
• 1 complimentary all-inclusive registration 

Package D – Sponsor a session (first come first served): $22,000 

• Name of Company on Sponsor List in program 
• Full page advertisement in program 
• Company logo and link on conference website 
• Company logo displayed on screen between sessions 
• Table display (premium location – sponsor’s choice) 
• Sponsor a session: includes introduction to the session chairs and 1 slide (2 min) to introduce the  company 
• 1 complimentary all-inclusive registration 
• Digital advertisement pre-conference announcement / program 
• Company information packet available in attendees’ registration materials 

Kevin Korpics (kevin@engconfintl.org) (+1-212-514-6760) may be contacted for invoicing and other  questions. Please make checks payable to:  

Engineering Conferences International 
Attn: Advancing Manufacturing of Cell & Gene Therapies VI  
32 Broadway, Suite 314  
New York, NY 10004  

Payment can also be made via wire transfer or credit card.  

You must reference your company name and the conference title “Advancing Manufacture of Cell & Gene  Therapies VII” or code (21-AT) so the contribution can be identified. Thank you in advance.

General Information about ECI

Engineering Conferences International (ECI) is a not-for-profit, global engineering conferences program, originally established in 1962 that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the conference provides morning and late afternoon or evening sessions in which major presentations are made. Poster sessions will be scheduled for evening discussion as well. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Smoking is prohibited at ECI conferences and conference functions.

  • Participant Login

    To sign in as a participant, please visit our registration portal.
  • Add Email

    To ensure receipt of ECI mailings, please add 'eci@informz.net' to your address book.
  • Page Sections